UNSPSC 51392229: Tramazoline hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C13H17N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4DG710Q678, chemically known as 4,5-dihydro-n-(5,6,7,8-tetrahydro-1-naphthalenyl)-1h-imidazol-2-amine but more generally known as tramazoline hydrochloride, which bears US NIH Compound Identifier 5524. European Medicines Agency schedules Tramazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04928MIG.

UNSPSC 51392229 Tramazoline hydrochloride is a Commodity code that does not align with the recent state and local opportunities posted under this code. The two most recent solicitations — Seminole County's procurement for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's request for information on direct-to-manufacturer prescription programs — involve active pharmaceutical ingredients and pharmacy benefit management, but neither directly concerns tramazoline hydrochloride, a nasal decongestant. The mismatch suggests this code receives little active procurement attention at the state and local level, or that recent opportunities have been tagged incorrectly in the source data.

The available opportunities indicate sporadic activity across different issuing bodies and states. Seminole County, Florida posted an IFB in June 2026 seeking annual supplies of naloxone and drug deactivation systems for quarterly delivery to its Community Health Building, with bids due July 26, 2023, while the Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription contracting models. These represent distinct procurement approaches — one a traditional IFB for physical product delivery, the other an exploratory market-intelligence gathering effort — and neither directly addresses the commodity named in the code.